The constitutive activation in ovarian cancer is a result of amplification of pathway components like PI3K subunits (p110), AKT isoforms (AKT1, AKT2, or AKT3), or members of the mTOR complexes (RICTOR, RAPTOR). Here, PIK3CA is linked to ovarian carcinoma.